- Status:
- Red
- Decision Date:
- September 2021
Comments
Monotherapy for the treatment of adults with recurrent or advanced
mismatch repair deficient/microsatellite instability-high endometrial cancer
that has progressed on or following prior treatment with a platinum‑containing regimen.
RED:
- NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. (Decision April 2022).
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again